DVAX
DYNAVAX TECHNOLOGIES CORP
DYNAVAX TECHNOLOGIES CORP (DVAX) has 1 SEC Form 4 filing (4 transaction rows) in the rolling window, disclosed by 0 distinct insiders. Most recent filing: Feb 10, 2026.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Ryan Spencer
- Employees:405
- HQ:EmeryVille, CA, US
- IPO:2004-02-19
No open-market insider trades for DVAX (DYNAVAX TECHNOLOGIES CORP) in the last 365 days.
Why this page may be quiet. Tracefour displays Form 4 open-market purchases (P) and sales (S): the two transaction codes that signal directional conviction. Restricted stock grants, option exercises, gifts, and tax-withholding sales are filed but intentionally not shown: they're disclosure mechanics, not buy/sell decisions.
Many large-cap executives trade through pre-scheduled 10b5-1 plans set months in advance and batch-disclosed each quarter, so the latest filing on EDGAR for a mega-cap can be weeks old without any insider actually choosing to trade in that window.